Nancy Ryan Gray - 07 Nov 2025 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Nancy Ryan Gray
Issuer symbol
LGND
Transactions as of
07 Nov 2025
Net transactions value
-$892,827
Form type
4
Filing time
12 Nov 2025, 16:45:03 UTC
Previous filing
10 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gray Nancy Ryan Director 555 HERITAGE DRIVE, SUITE 200, JUPITER By: /s/ Andrew Reardon, Attorney-in-Fact For: Nancy Ryan Gray 12 Nov 2025 0001714949

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $235,372 +3,556 +44% $66.19 11,650 07 Nov 2025 Direct
transaction LGND Common Stock Sale $730,580 -3,556 -31% $205.45 8,094 07 Nov 2025 Direct
transaction LGND Common Stock Options Exercise $221,814 +3,015 +37% $73.57 11,109 07 Nov 2025 Direct
transaction LGND Common Stock Sale $619,432 -3,015 -27% $205.45 8,094 07 Nov 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Options Exercise $0 -3,556 -100% $0.000000 0 07 Nov 2025 Common Stock 3,556 $66.19 Direct F1
transaction LGND Non-Qualified Stock Option (right to buy) Options Exercise $0 -3,015 -100% $0.000000 0 07 Nov 2025 Common Stock 3,015 $73.57 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Option was previously reported as a Grant of 4,071 shares, which vested in full on June 06, 2020, at an exercise price of $113.5900 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
F2 This Option was previously reported as a Grant of 3,452 shares, which vested in full on August 18, 2020, at an exercise price of $126.2600 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer.